ACE-031 vs YK-11
A side-by-side research comparison of ACE-031 and YK-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ACE-031 | YK-11 |
|---|---|---|
| Full name | ACE-031 (Soluble ActRIIB-Fc Fusion) | YK-11 (Myostatin Inhibitor / SARM) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes. | Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation. |
| Molecular weight | ~90,000 Da | 430.54 Da |
| Half-life | 10-14 days | ~6-10 hours |
| Bioavailability | High (SubQ) | ~70% oral |
| Typical dose | 0.3-3 mg/kg | 5-10 mg |
| Frequency | Every 2-4 weeks | Once daily |
| Route | Subcutaneous | Oral |
ACE-031 reported benefits
- Multi-ligand pathway inhibition
- Lean mass increase
- Bone density increase
- Infrequent dosing
- Functional strength improvement
YK-11 reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Related comparisons
Research and educational reference only. Not medical advice.